Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iC9.CAR.B7-H3 T cells in Refractory Pancreatic Ductal Adenocarcinoma
NCT06158139Phase 1Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jul 2024
- Primary completion
- Apr 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iC9-CAR.B7-H3 T cells in pancreatic ductal adenocarcinoma (PDAC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Number of participants with adverse event at 4 weeks, Cytokine Release Syndrome at 4 weeks and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
iC9-CAR.B7-H3 T cells
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06158139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158139.